KAIROS PHARMA, LTD. Amortization of Debt Discount (Premium)
KAIROS PHARMA, LTD. (KAPA) reported Amortization of Debt Discount (Premium) of $154.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-03-31
- KAIROS PHARMA, LTD. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- KAIROS PHARMA, LTD. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $115.00K, a 1050.00% increase year-over-year.
- KAIROS PHARMA, LTD. amortization of debt discount (premium) for the quarter ending 2024-06-30 was $19.00K.
- KAIROS PHARMA, LTD. amortization of debt discount (premium) for the quarter ending 2024-03-31 was $20.00K.
- KAIROS PHARMA, LTD. amortization of debt discount (premium) for fiscal 2024 was $154.00K, a 175.00% increase from fiscal 2023.
- KAIROS PHARMA, LTD. amortization of debt discount (premium) for fiscal 2023 was $56.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $115.00K derived: sum of 2 quarters · filed 2026-03-31 | $134.00K derived: sum of 3 quarters · filed 2026-03-31 | $154.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $115.00K 10-Q · filed 2025-11-14 | $134.00K derived: sum of 2 quarters · filed 2025-11-14 | $154.00K 10-Q · filed 2025-11-14 | $180.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $19.00K 10-Q · filed 2025-08-12 | $39.00K 10-Q · filed 2025-08-12 | $65.00K derived: sum of 3 quarters · filed 2025-08-12 | $75.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-14 | $46.00K derived: sum of 2 quarters · filed 2025-05-14 | $56.00K derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $36.00K derived: sum of 2 quarters · filed 2025-04-15 | $56.00K 10-K · filed 2025-04-15 | |
| 2023-09-30 | $10.00K 10-Q · filed 2024-11-14 | $30.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |